Neorphys – Product Pipeline Review – Q1 2011

Date: March 1, 2011
Pages: 29
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: N4A1AF04014EN
Leaflet:

Download PDF Leaflet

Neorphys - Product Pipeline Review - Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Neorphys - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Neorphys - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Neorphys human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Neorphys with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Neorphys’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Neorphys’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Neorphys in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Neorphys’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Neorphys.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Neorphys and identify potential opportunities in those areas.
Table of Contents
List of Tables
List of Figures
Neorphys Snapshot
Neorphys Overview
Key Information
Key Facts
Neorphys – Research and Development Overview
Key Therapeutic Areas
Neorphys – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Neorphys – Pipeline Products Glance
Neorphys–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Neorphys – Drug Profiles
Neo1507
Product Description
R&D Progress
Neo1509
Product Description
Mechanism of Action
R&D Progress
Neo1528
Product Description
Mechanism of Action
R&D Progress
Neo15xx
Product Description
Mechanism of Action
R&D Progress
Neo20xx
Product Description
Mechanism of Action
R&D Progress
Neorphys – Pipeline Analysis
Neorphys – Pipeline Products by Therapeutic Class
Neorphys - Pipeline Products By Target
Neorphys – Pipeline Products by Route of Administration
Neorphys – Pipeline Products by Molecule Type
Neorphys – Locations And Subsidiaries
Head Office
Recent Developments
Oct 12, 2006: Neorphys Files The First Patent For Neo1507.
Financial Deals Landscape
Neorphys, Deals Summary, 2004 to 2011
Neorphys Detailed Deal Summary
Venture Financing
Neorphys Secures $1.72 Million In Second Round Of Financing
Neorphys Secures $1.4 Million In Seed Round Of Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Neorphys – Pipeline by Therapy Area and Indication, 2011
Neorphys – Pipeline by Stage of Development, 2011
Neorphys – Monotherapy Products in Pipeline, 2011
Neorphys - Pipeline By Therapeutic Class, 2011
Neorphys - Pipeline By Target, 2011
Neorphys – Pipeline By Route of Administration, 2011
Neorphys – Pipeline By Molecule Type, 2011
Neorphys, Deals Summary, 2004 to 2011

LIST OF FIGURES

Neorphys – Pipeline by Therapy Area and Indication, 2011
Neorphys – Pipeline by Stage of Development, 2011
Neorphys – Monotherapy Products in Pipeline, 2011
Neorphys – Product Pipeline Review – Q4 2010 US$ 450.00 Nov, 2010 · 27 pages
Myelofibrosis - Pipeline Review, H2 2014 US$ 1,800.00 Oct, 2014 · 161 pages
Hyperuricemia - Pipeline Review, Q2 2011 US$ 450.00 May, 2011 · 39 pages

Ask Your Question

Neorphys – Product Pipeline Review – Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: